173 related articles for article (PubMed ID: 21547513)
61. The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome.
Vieira CS; Martins WP; Fernandes JB; Soares GM; dos Reis RM; de Sá MF; Ferriani RA
Contraception; 2012 Sep; 86(3):268-75. PubMed ID: 22464410
[TBL] [Abstract][Full Text] [Related]
62. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.
Diamanti-Kandarakis E; Kouli CR; Bergiele AT; Filandra FA; Tsianateli TC; Spina GG; Zapanti ED; Bartzis MI
J Clin Endocrinol Metab; 1999 Nov; 84(11):4006-11. PubMed ID: 10566641
[TBL] [Abstract][Full Text] [Related]
63. Evaluation of the correlation between insulin like factor 3, polycystic ovary syndrome, and ovarian maldescent.
Seyam E; Hefzy E
Gynecol Endocrinol; 2018 Jun; 34(6):481-488. PubMed ID: 29254383
[TBL] [Abstract][Full Text] [Related]
64. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.
Fenkci SM; Fenkci V; Oztekin O; Rota S; Karagenc N
Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560
[TBL] [Abstract][Full Text] [Related]
65. A 20-year follow-up of young women with polycystic ovary syndrome.
Carmina E; Campagna AM; Lobo RA
Obstet Gynecol; 2012 Feb; 119(2 Pt 1):263-9. PubMed ID: 22270277
[TBL] [Abstract][Full Text] [Related]
66. Relation of NT-probnp levels and cardiovascular disease risk factors in lean women with polycystic ovary syndrome.
Karadağ C; Yoldemir T
J Obstet Gynaecol; 2019 Nov; 39(8):1154-1159. PubMed ID: 31215274
[TBL] [Abstract][Full Text] [Related]
67. Eight-hour time-restricted feeding improves endocrine and metabolic profiles in women with anovulatory polycystic ovary syndrome.
Li C; Xing C; Zhang J; Zhao H; Shi W; He B
J Transl Med; 2021 Apr; 19(1):148. PubMed ID: 33849562
[TBL] [Abstract][Full Text] [Related]
68. Polycystic ovary syndrome: relationship between insulin sensitivity, sex hormone levels and ovarian stromal blood flow.
Loverro G; Vicino M; Lorusso F; Vimercati A; Greco P; Selvaggi L
Gynecol Endocrinol; 2001 Apr; 15(2):142-9. PubMed ID: 11379011
[TBL] [Abstract][Full Text] [Related]
69. Does hyperandrogenism have an effect on hearing loss in patients with polycystic ovary syndrome?
Oghan F; Coksuer H
Auris Nasus Larynx; 2012 Aug; 39(4):365-8. PubMed ID: 21862266
[TBL] [Abstract][Full Text] [Related]
70. The role of chronic anovulation in the polycystic ovary syndrome: normalization of sex-hormone-binding globulin levels after clomiphene-induced ovulation.
Eden JA; Place J; Carter GD; Alaghband-Zadeh J; Pawson ME
Clin Endocrinol (Oxf); 1989 Mar; 30(3):323-32. PubMed ID: 2512039
[TBL] [Abstract][Full Text] [Related]
71. Are there differences in basal thrombophilias and C-reactive protein between women with or without PCOS?
Sánchez-Ferrer ML; Prieto-Sánchez MT; Corbalán-Biyang S; Mendiola J; Adoamnei E; Hernández-Peñalver AI; Carmona-Barnosi A; Salido-Fiérrez EJ; Torres-Cantero AM
Reprod Biomed Online; 2019 Jun; 38(6):1018-1026. PubMed ID: 31023609
[TBL] [Abstract][Full Text] [Related]
72. Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS).
Atiomo WU; Fox R; Condon JE; Shaw S; Friend J; Prentice AG; Wilkin TJ
Clin Endocrinol (Oxf); 2000 Apr; 52(4):487-92. PubMed ID: 10762292
[TBL] [Abstract][Full Text] [Related]
73. Insulin-like factor 3 -- a new hormone related to polycystic ovary syndrome?
Szydlarska D; Grzesiuk W; Trybuch A; Kondracka A; Kowalik I; Bar-Andziak E
Endokrynol Pol; 2012; 63(5):356-61. PubMed ID: 23115068
[TBL] [Abstract][Full Text] [Related]
74. The association of serum androgens and insulin resistance with fat distribution in polycystic ovary syndrome.
Yucel A; Noyan V; Sagsoz N
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):81-6. PubMed ID: 16337726
[TBL] [Abstract][Full Text] [Related]
75. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.
Falsetti L; Pasinetti E
Acta Obstet Gynecol Scand; 1995 Jan; 74(1):56-60. PubMed ID: 7856434
[TBL] [Abstract][Full Text] [Related]
76. Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular risk in patients with polycystic ovary syndrome.
Karbek B; Ozbek M; Karakose M; Topaloglu O; Bozkurt NC; Cakır E; Aslan MS; Delibasi T
J Ovarian Res; 2014 Mar; 7():31. PubMed ID: 24628831
[TBL] [Abstract][Full Text] [Related]
77. Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome.
Glintborg D; Altinok M; Mumm H; Buch K; Ravn P; Andersen M
Hum Reprod; 2014 Aug; 29(8):1773-9. PubMed ID: 24903198
[TBL] [Abstract][Full Text] [Related]
78. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables.
Holte J; Bergh T; Berne C; Lithell H
Clin Endocrinol (Oxf); 1994 Oct; 41(4):463-71. PubMed ID: 7955457
[TBL] [Abstract][Full Text] [Related]
79. Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome.
Mather KJ; Verma S; Corenblum B; Anderson TJ
J Clin Endocrinol Metab; 2000 May; 85(5):1851-6. PubMed ID: 10843164
[TBL] [Abstract][Full Text] [Related]
80. Are progranulin levels associated with polycystic ovary syndrome and its possible metabolic effects in adolescents and young women?
Ersoy AO; Tokmak A; Ozler S; Oztas E; Ersoy E; Celik HT; Erdamar H; Yilmaz N
Arch Gynecol Obstet; 2016 Aug; 294(2):403-9. PubMed ID: 27071619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
